

Please replace the paragraph, beginning at page 5, line 20, with the following rewritten paragraph:

--Preferred PTH antagonists of the present invention have an amino acid sequence from between PTH₂₋₈₄ (SEQ ID NO:1) and PTH₃₄₋₈₄ (SEQ ID NO:3) or a conservatively substituted variant thereof exhibiting PTH antagonist activity, with the most preferred form being from between PTH₃₋₈₄ (SEQ ID NO:2) and PTH₂₈₋₈₄ (SEQ ID NO:8).--

In the Sequence Listing:

Please replace the paper copy of the previously submitted sequence listing with the paper copy of the substitute Sequence Listing submitted herewith. A computer readable copy (CRF copy) of the substitute sequence listing accompanies this preliminary amendment.

In the Claims:

Please amend claim 1 as follows:

1. (Amended) A method for treating a patient that has osteoporosis and is being administered cyclase activating parathyroid hormone (CAP) or analogues thereof comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) having amino acid sequence from between PTH₂₋₈₄ (SEQ ID NO:1) and PTH₃₄₋₈₄ (SEQ ID NO:3) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

Please amend claim 2 as follows:

2. (Amended) The method of claim 1 wherein the peptide has an amino acid sequence from between PTH₃₋₈₄ (SEQ ID NO:2) and PTH₂₈₋₈₄ (SEQ ID NO:8).

Please amend claim 5 as follows:

5. (Amended) A method for treating a patient that has osteoporosis comprising administering a cyclase inhibiting parathyroid hormone peptide (CIP) having amino acid sequence from between PTH₂₋₈₄ (SEQ ID NO:1) and PTH₃₄₋₈₄ (SEQ ID NO:3) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

Please amend claim 6 as follows:

6. (Amended) The method of claim 5 wherein the peptide has an amino acid sequence from between PTH₃₋₈₄ (SEQ ID NO:2) and PTH₂₈₋₈₄ (SEQ ID NO:8).